NewSquare Capital LLC Increases Stake in Sanofi (NASDAQ:SNY)

NewSquare Capital LLC raised its stake in shares of Sanofi (NASDAQ:SNY) by 3.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 106,697 shares of the company’s stock after buying an additional 3,723 shares during the quarter. NewSquare Capital LLC’s holdings in Sanofi were worth $5,239,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the stock. Rise Advisors LLC grew its holdings in shares of Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after purchasing an additional 251 shares in the last quarter. Salem Investment Counselors Inc. purchased a new position in shares of Sanofi in the fourth quarter valued at $27,000. Venturi Wealth Management LLC grew its holdings in shares of Sanofi by 163.5% in the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock valued at $27,000 after purchasing an additional 332 shares in the last quarter. CNB Bank purchased a new position in shares of Sanofi in the third quarter valued at $39,000. Finally, Farmers & Merchants Trust Co of Chambersburg PA grew its holdings in shares of Sanofi by 115.6% in the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company’s stock valued at $37,000 after purchasing an additional 400 shares in the last quarter. 10.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Trading Up 1.1 %

Shares of NASDAQ:SNY traded up $0.54 on Tuesday, hitting $47.69. 1,664,859 shares of the company’s stock were exchanged, compared to its average volume of 1,914,748. Sanofi has a 12 month low of $42.63 and a 12 month high of $57.82. The stock has a market capitalization of $120.64 billion, a price-to-earnings ratio of 20.21, a price-to-earnings-growth ratio of 1.62 and a beta of 0.61. The business’s 50 day simple moving average is $47.58 and its two-hundred day simple moving average is $48.45. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a return on equity of 27.47% and a net margin of 12.56%. The business had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $13.02 billion. Analysts anticipate that Sanofi will post 4.11 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be given a dividend of $1.478 per share. This represents a dividend yield of 2.98%. This is an increase from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s dividend payout ratio (DPR) is 58.47%.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Morgan Stanley started coverage on shares of Sanofi in a report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 target price for the company. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Finally, TheStreet downgraded Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $55.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.